> top > docs > PubMed:25731749 > annotations

PubMed:25731749 JSONTXT

Annnotations TAB JSON ListView MergeView

c_corpus

Id Subject Object Predicate Lexical cue
T1 41-46 PR:Q5S006 denotes LRRK2
T2 41-46 PR:000003033 denotes LRRK2
T3 41-46 PR:Q5S007 denotes LRRK2
T5 108-111 PR:P63003-1 denotes rat
T6 108-111 PR:Q2G0B1 denotes rat
T7 108-111 PR:Q8VHJ4 denotes rat
T4 108-111 10116 denotes rat
T8 108-111 D051381 denotes rat
T13 121-140 D010300 denotes Parkinson's disease
T14 121-140 D010300 denotes Parkinson's disease
T18 159-166 6308 denotes leucine
T19 159-166 SO:0001437 denotes leucine
T17 159-166 CHEBI:15603 denotes leucine
T20 159-166 D007930 denotes leucine
T21 159-166 CHEBI:25017 denotes leucine
T22 159-166 D007930 denotes leucine
T23 172-178 SO:0001068 denotes repeat
T24 189-194 PR:Q5S006 denotes LRRK2
T25 189-194 PR:000003033 denotes LRRK2
T26 189-194 PR:Q5S007 denotes LRRK2
T27 196-200 SO:0000704 denotes gene
T28 207-217 D000067562 denotes late-onset
T29 207-217 D000067562 denotes late-onset
T30 219-237 C566739 denotes autosomal dominant
T35 238-257 D010300 denotes Parkinson's disease
T36 238-257 D010300 denotes Parkinson's disease
T39 264-269 PR:Q5S006 denotes LRRK2
T40 264-269 PR:000003033 denotes LRRK2
T41 264-269 PR:Q5S007 denotes LRRK2
T42 290-296 D020558 denotes GTPase
T43 340-348 SO:0000109 denotes mutation
T44 362-377 GO:0016301 denotes kinase activity
T45 381-386 PR:Q5S006 denotes LRRK2
T46 381-386 PR:000003033 denotes LRRK2
T47 381-386 PR:Q5S007 denotes LRRK2
T48 411-416 PR:Q5S006 denotes LRRK2
T49 411-416 PR:000003033 denotes LRRK2
T50 411-416 PR:Q5S007 denotes LRRK2
T51 543-558 GO:0016301 denotes kinase activity
T52 562-567 PR:Q5S006 denotes LRRK2
T53 562-567 PR:000003033 denotes LRRK2
T54 562-567 PR:Q5S007 denotes LRRK2
T55 618-624 D012377 denotes rodent
T56 728-733 PR:Q5S006 denotes LRRK2
T57 728-733 PR:000003033 denotes LRRK2
T58 728-733 PR:Q5S007 denotes LRRK2
T59 786-791 PR:Q5S006 denotes LRRK2
T60 786-791 PR:000003033 denotes LRRK2
T61 786-791 PR:Q5S007 denotes LRRK2
T62 832-847 GO:0016301 denotes kinase activity
T63 851-856 PR:Q5S006 denotes LRRK2
T64 851-856 PR:000003033 denotes LRRK2
T65 851-856 PR:Q5S007 denotes LRRK2
T66 897-902 D006801 denotes human
T67 947-952 D006801 denotes human
T68 953-962 SO:0000817 denotes wild-type
T69 1004-1009 PR:Q5S006 denotes LRRK2
T70 1004-1009 PR:000003033 denotes LRRK2
T71 1004-1009 PR:Q5S007 denotes LRRK2
T73 1017-1020 PR:P63003-1 denotes rat
T74 1017-1020 PR:Q2G0B1 denotes rat
T75 1017-1020 PR:Q8VHJ4 denotes rat
T72 1017-1020 10116 denotes rat
T76 1017-1020 D051381 denotes rat
T77 1021-1029 UBERON:0002435 denotes striatum
T78 1021-1029 UBERON:0005383 denotes striatum
T79 1031-1036 PR:Q5S006 denotes LRRK2
T80 1031-1036 PR:000003033 denotes LRRK2
T81 1031-1036 PR:Q5S007 denotes LRRK2
T82 1077-1085 UBERON:0002435 denotes striatum
T83 1077-1085 UBERON:0005383 denotes striatum
T84 1102-1107 PR:Q5S006 denotes LRRK2
T85 1102-1107 PR:000003033 denotes LRRK2
T86 1102-1107 PR:Q5S007 denotes LRRK2
T87 1102-1115 D000071158 denotes LRRK2 protein
T91 1108-1115 PR:000000001 denotes protein
T88 1108-1115 GO:0003675 denotes protein
T92 1108-1115 SO:0000104 denotes protein
T93 1154-1159 UBERON:6110636 denotes brain
T94 1154-1159 UBERON:0000955 denotes brain
T95 1161-1166 D006801 denotes Human
T96 1167-1172 PR:Q5S006 denotes LRRK2
T97 1167-1172 PR:000003033 denotes LRRK2
T98 1167-1172 PR:Q5S007 denotes LRRK2
T100 1220-1223 PR:P63003-1 denotes rat
T101 1220-1223 PR:Q2G0B1 denotes rat
T102 1220-1223 PR:Q8VHJ4 denotes rat
T99 1220-1223 10116 denotes rat
T103 1220-1223 D051381 denotes rat
T104 1224-1232 UBERON:0002435 denotes striatum
T105 1224-1232 UBERON:0005383 denotes striatum
T106 1255-1260 PR:Q5S006 denotes LRRK2
T107 1255-1260 PR:000003033 denotes LRRK2
T108 1255-1260 PR:Q5S007 denotes LRRK2
T109 1310-1319 P68197 denotes ubiquitin
T110 1310-1319 P84589 denotes ubiquitin
T111 1310-1319 P19848 denotes ubiquitin
T113 1310-1319 Q8SWD4 denotes ubiquitin
T114 1310-1319 P62975 denotes ubiquitin
T115 1310-1319 P69310 denotes ubiquitin
T116 1310-1319 PR:000035728 denotes ubiquitin
T117 1310-1319 P69317 denotes ubiquitin
T118 1310-1319 Q865C5 denotes ubiquitin
T120 1310-1319 P69313 denotes ubiquitin
T122 1310-1319 P69326 denotes ubiquitin
T119 1310-1319 D025801 denotes ubiquitin
T121 1310-1319 CHEBI:17471 denotes ubiquitin
T112 1310-1319 GO:0031386 denotes ubiquitin
T123 1355-1362 GO:0043005 denotes neurite
T124 1497-1505 SO:0000109 denotes mutation
T125 1580-1585 PR:Q5S006 denotes LRRK2
T126 1580-1585 PR:000003033 denotes LRRK2
T127 1580-1585 PR:Q5S007 denotes LRRK2
T128 1593-1601 UBERON:0002435 denotes striatum
T129 1593-1601 UBERON:0005383 denotes striatum
T130 1615-1630 GO:0016301 denotes kinase activity
T131 1674-1682 SO:0000109 denotes mutation
T132 1766-1774 SO:0000109 denotes mutation
T133 1792-1797 UBERON:6110636 denotes brain
T134 1792-1797 UBERON:0000955 denotes brain
T135 1837-1847 CHEBI:35222 denotes inhibitors
T136 1897-1902 PR:Q5S006 denotes LRRK2
T137 1897-1902 PR:000003033 denotes LRRK2
T138 1897-1902 PR:Q5S007 denotes LRRK2
T139 1934-1940 D012377 denotes rodent
T140 2013-2018 PR:Q5S006 denotes LRRK2
T141 2013-2018 PR:000003033 denotes LRRK2
T142 2013-2018 PR:Q5S007 denotes LRRK2

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 219-237 HP_0000006 denotes autosomal dominant
T2 238-247 HP_0001300 denotes Parkinson
T3 642-671 HP_0002344 denotes progressive neurodegeneration
T4 654-671 HP_0002180 denotes neurodegeneration
T5 866-883 HP_0002180 denotes neurodegeneration
T6 2028-2045 HP_0002180 denotes neurodegeneration

UseCases_ArguminSci_Discourse

Id Subject Object Predicate Lexical cue
T1 0-33 DRI_Challenge denotes Adenoviral-mediated expression of
T2 34-46 Token_Label.OUTSIDE denotes G2019S LRRK2
T3 47-141 DRI_Challenge denotes induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
T4 142-263 DRI_Approach denotes Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene cause late-onset, autosomal dominant Parkinson's disease (PD).
T5 264-316 DRI_Unspecified denotes LRRK2 contains functional GTPase and kinase domains.
T6 317-403 DRI_Background denotes The most common G2019S mutation enhances the kinase activity of LRRK2 in vitro whereas
T7 404-416 Token_Label.OUTSIDE denotes G2019S LRRK2
T8 417-494 DRI_Background denotes expression in cultured neurons induces toxicity in a kinase-dependent manner.
T9 495-582 DRI_Background denotes These observations suggest a potential role for kinase activity in LRRK2-associated PD.
T10 583-720 DRI_Approach denotes We have recently developed a novel rodent model of PD with progressive neurodegeneration induced by the adenoviral-mediated expression of
T11 721-733 Token_Label.OUTSIDE denotes G2019S LRRK2
T12 733-734 DRI_Approach denotes .
T13 735-884 DRI_Outcome denotes In the present study, we further characterize this LRRK2 model and determine the contribution of kinase activity to LRRK2-mediated neurodegeneration.
T14 885-973 DRI_Background denotes Recombinant human adenoviral vectors were employed to deliver human wild-type, G2019S or
T15 974-1009 Token_Label.OUTSIDE denotes kinase-inactive G2019S/D1994N LRRK2
T16 1010-1030 DRI_Background denotes to the rat striatum.
T17 1031-1160 DRI_Outcome denotes LRRK2-dependent pathology was assessed in the striatum, a region where LRRK2 protein is normally enriched in the mammalian brain.
T18 1161-1233 DRI_Background denotes Human LRRK2 variants are robustly expressed throughout the rat striatum.
T19 1234-1247 DRI_Challenge denotes Expression of
T20 1248-1260 Token_Label.OUTSIDE denotes G2019S LRRK2
T21 1261-1445 DRI_Challenge denotes selectively induces the accumulation of neuronal ubiquitin-positive inclusions accompanied by neurite degeneration and the altered distribution of axonal phosphorylated neurofilaments.
T22 1446-1572 DRI_Challenge denotes Importantly, the introduction of a kinase-inactive mutation (G2019S/D1994N) completely ameliorates the pathological effects of
T23 1573-1585 Token_Label.OUTSIDE denotes G2019S LRRK2
T24 1586-1683 DRI_Challenge denotes in the striatum supporting a kinase activity-dependent mechanism for this PD-associated mutation.
T25 1684-1917 DRI_Outcome denotes Collectively, our study further elucidates the pathological effects of the G2019S mutation in the mammalian brain and supports the development of kinase inhibitors as a potential therapeutic approach for treating LRRK2-associated PD.
T26 1918-2046 DRI_Outcome denotes This adenoviral rodent model provides an important tool for elucidating the molecular basis of LRRK2-mediated neurodegeneration.

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 142-263 DRI_Approach denotes Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene cause late-onset, autosomal dominant Parkinson's disease (PD).
T2 317-403 DRI_Background denotes The most common G2019S mutation enhances the kinase activity of LRRK2 in vitro whereas
T3 417-494 DRI_Background denotes expression in cultured neurons induces toxicity in a kinase-dependent manner.
T4 495-582 DRI_Background denotes These observations suggest a potential role for kinase activity in LRRK2-associated PD.
T5 583-720 DRI_Approach denotes We have recently developed a novel rodent model of PD with progressive neurodegeneration induced by the adenoviral-mediated expression of
T6 733-734 DRI_Approach denotes .
T7 735-884 DRI_Outcome denotes In the present study, we further characterize this LRRK2 model and determine the contribution of kinase activity to LRRK2-mediated neurodegeneration.
T8 885-973 DRI_Background denotes Recombinant human adenoviral vectors were employed to deliver human wild-type, G2019S or
T9 1010-1030 DRI_Background denotes to the rat striatum.
T10 1031-1160 DRI_Outcome denotes LRRK2-dependent pathology was assessed in the striatum, a region where LRRK2 protein is normally enriched in the mammalian brain.
T11 1161-1233 DRI_Background denotes Human LRRK2 variants are robustly expressed throughout the rat striatum.
T12 1234-1247 DRI_Challenge denotes Expression of
T13 1261-1445 DRI_Challenge denotes selectively induces the accumulation of neuronal ubiquitin-positive inclusions accompanied by neurite degeneration and the altered distribution of axonal phosphorylated neurofilaments.
T14 1446-1572 DRI_Challenge denotes Importantly, the introduction of a kinase-inactive mutation (G2019S/D1994N) completely ameliorates the pathological effects of
T15 1586-1683 DRI_Challenge denotes in the striatum supporting a kinase activity-dependent mechanism for this PD-associated mutation.
T16 1684-1917 DRI_Outcome denotes Collectively, our study further elucidates the pathological effects of the G2019S mutation in the mammalian brain and supports the development of kinase inhibitors as a potential therapeutic approach for treating LRRK2-associated PD.
T17 1918-2046 DRI_Outcome denotes This adenoviral rodent model provides an important tool for elucidating the molecular basis of LRRK2-mediated neurodegeneration.

DisGeNET5_variant_disease

Id Subject Object Predicate Lexical cue
25731749-0#34#40#geners34637584 34-40 geners34637584 denotes G2019S
25731749-0#121#140#diseaseC0030567 121-140 diseaseC0030567 denotes Parkinson's disease
25731749-12#75#81#geners34637584 1759-1765 geners34637584 denotes G2019S
25731749-12#230#232#diseaseC3489791 1914-1916 diseaseC3489791 denotes PD
34#40#geners34637584121#140#diseaseC0030567 25731749-0#34#40#geners34637584 25731749-0#121#140#diseaseC0030567 associated_with G2019S,Parkinson's disease
75#81#geners34637584230#232#diseaseC3489791 25731749-12#75#81#geners34637584 25731749-12#230#232#diseaseC3489791 associated_with G2019S,PD

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
25731749-0#41#46#gene120892 41-46 gene120892 denotes LRRK2
25731749-0#121#140#diseaseC0030567 121-140 diseaseC0030567 denotes Parkinson's disease
25731749-12#213#218#gene120892 1897-1902 gene120892 denotes LRRK2
25731749-12#230#232#diseaseC3489791 1914-1916 diseaseC3489791 denotes PD
41#46#gene120892121#140#diseaseC0030567 25731749-0#41#46#gene120892 25731749-0#121#140#diseaseC0030567 associated_with LRRK2,Parkinson's disease
213#218#gene120892230#232#diseaseC3489791 25731749-12#213#218#gene120892 25731749-12#230#232#diseaseC3489791 associated_with LRRK2,PD